Industry News (Protease Inhibitors)

HIV Protease Inhibitor To Be Launched in Japan

Published in AIDS Weekly, October 11th, 1999

Vertex Pharmaceuticals Inc., Cambridge, Massachusetts, and Kissei Pharmaceutical Co., Ltd., Matsumoto-City, Japan, announced that Kissei is launching Prozei (amprenavir), an orally-administered HIV protease inhibitor, in Japan.

Prozei was approved in mid-September 1999 through a new fast-track evaluation process instituted by the Japanese Ministry of Health and Welfare for innovative HIV therapies, and the drug was to be available to patients beginning October 1.

Prozei (known outside of Japan by the trade name Agenerase) was discovered at Vertex and has been developed in Japan by Kissei. Prozei is indicated in combination with other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry